Brightseed, a life science company specializing in AI-powered discovery, announced a major expansion of its proprietary data set of bioactives.

The database now includes 21 million natural compounds and is nearly twice the size it was in 2023. The platform has also become 98% more cost-efficient since the company started in 2018, Brightseed reported.

The database expansion, combined with advances in profiling and analysis, will strengthen the platform’s ability to generate novel, high-confidence insights.

Brightseed’s platform generates functional interference models across more than 23 health categories. Its corporate partners can use these insights to commercialize natural compounds in agriculture, health, nutraceuticals, animal health, and more.

One consumer health partner, for example, is leveraging Brightseed’s model to discover complementary pathways to the GLP-1 signaling cascade, with a growing lineup of candidate molecules already identified.

“The real story here is not just the size of our dataset, but its productivity,” said Lee Chae, PhD, co-founder and CEO of Brightseed. “Brightseed’s platform is built off of the world’s largest biologically connected and actionable library of proprietary natural compounds, and we’ve only tapped a small percentage of this dataset so far. There’s still so much gold for us to explore and discover. These endless possibilities are our moat.”

Unlike public databases or generalized AI training data, Brightseed’s platform maps its proprietary dataset of small molecules to biological mechanisms and human health outcomes, accelerating discovery and validation.

According to Brightseed, its AI discovery engine, Forager, enables customers to:

• Identify relationships among novel bioactives and mechanisms not found in public literature
• Evaluate biological relevance and feasibility earlier in development
• Generate differentiated, IP-ready innovation opportunities
• Increase the probability of commercial success